News Merck & Co., Inc.

Equities

MRK

US58933Y1055

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 09:46:46 2025-06-13 EDT			5-day change	1st Jan Change
82.07 ^USD	+0.31%		+3.36%	-17.95%

08:10am	Merck: FDA approves Keytruda for head and neck cancer	CF
07:50am	FDA Approves Merck's Anti-PD-1 Therapy	CI

Merck: FDA approves Keytruda for head and neck cancer	08:10am	CF
FDA Approves Merck's Anti-PD-1 Therapy	07:50am	CI
Merck Receives FDA Approval for Treatment of Head, Neck Cancers	07:35am	DJ
Merck Says FDA Approves Keytruda for Head and Neck Cancer With PD-L1 Expression	07:19am	MT
FDA Approves KEYTRUDA® (pembrolizumab) for PD-L1+ Resectable Locally Advanced Head & Neck Squamous Cell Carcinoma as Neoadjuvant Treatment, Continued as Adjuvant Treatment Combined With Radiotherapy With or Without Cisplatin Then as a Single Agent	06:46am	BU
Merck Animal Health Gets EU Positive Opinion for Numelvi Tablets for Dogs	06-12	MT
Merck Animal Health Receives EU Cvmp Positive Opinion For Numelvi Tablets For Dogs	06-12	RE
Merck Animal Health Receives EU CVMP Positive Opinion for NUMELVI™ (atinvicitinib) Tablets for Dogs	06-12	BU
Exclusive-Kennedy's new vaccine adviser was expert witness against Merck vaccine	06-12	RE
US Senators Introduce Bill to Ban Direct-to-Consumer Drug Ads	06-12	MT
Kennedy's new vaccine adviser was expert witness against Merck vaccine	06-12	RE
BioNTech takes over CureVac in $1.25 billion all-stock deal among COVID rivals	06-12	RE
Merck: Phase 3 trial for dengue vaccine	06-12	CF
Merck Initiates Phase 3 Study Evaluating Dengue Vaccine Candidate	06-12	CI
Merck Starts Phase 3 Trial of Dengue Vaccine	06-12	MT
Merck Initiates Phase 3 Study Evaluating Dengue Vaccine Candidate	06-12	RE
Merck Initiates Phase 3 Study Evaluating Dengue Vaccine Candidate	06-12	BU
Worldwide Healthcare Trust trails benchmark in "challenging" year	06-11	AN
BioInvent Announces Promising Phase 1 Data of BI-1206 in Combination with KEYTRUDA® (pembrolizumab) in Solid Tumors	06-11	AQ
Drug pricing reform talks with US government lack clarity, industry executives say	06-10	RE
Merck & Co., Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 10:00 AM	06-10
Vaccine stocks muted as investors assess Kennedy's overhaul of key panel	06-10	RE
Insmed's drug for rare lung disease achieves 'home run' in mid-stage trial	06-10	RE
US FDA approves Merck's RSV antibody for infants	06-10	RE
US FDA approves Merck's RSV antibody for infants	06-09	RE

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Merck & Co., Inc.

Equities

MRK

US58933Y1055

Pharmaceuticals

Filters